Equities

Seed Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7743:TYO

Seed Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)592.00
  • Today's Change-1.00 / -0.17%
  • Shares traded21.80k
  • 1 Year change+17.46%
  • Beta0.9412
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Seed Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of contact lenses, as well as the sale of contact lens care products and other products. The Contact Lens and Care Products segment sells contact lenses, care products, and related products. Contact lens products include hard lenses, soft lenses, disposable lenses, orthokeratology lenses, and related products such as optical instruments. Contact lens care products include preservatives, cleaning solutions, enzymatic cleaning solutions, chemical disinfectants, storage cases, and others. The other businesses include eyeglass frames, eyeglass fixtures, intraocular lenses, and others.

  • Revenue in JPY (TTM)33.55bn
  • Net income in JPY1.38bn
  • Incorporated1957
  • Employees985.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Koken Ltd11.18bn776.88m9.81bn321.0012.230.71548.210.8776157.25157.252,268.412,688.030.5421.913.1834,839,600.003.773.974.625.0745.8346.446.957.561.6721.320.293524.851.664.582.9914.21-2.196.96
Yamashita Health Care Holdings Inc63.77bn412.00m9.91bn613.0023.401.0915.480.1553165.78165.7825,574.613,576.032.4314.255.39104,027,700.001.562.244.396.5313.5013.100.6430.89750.945--0.0032.954.76-0.05346.216.0343.356.79
Create Medic Co Ltd13.57bn762.91m10.94bn1.00k12.920.60768.180.80687.6087.601,563.181,863.230.71481.824.9413,545,480.004.023.044.543.5844.6244.515.624.635.1741.710.045860.323.533.74445.963.0114.010.00
JMS Co Ltd68.14bn157.00m11.01bn5.47k69.540.26844.110.16156.406.402,780.131,658.270.81552.553.7912,458,400.000.06460.74270.09361.1023.0323.520.07930.88361.0841.060.388171.626.833.56347.22-46.21-1.640.00
DVx Inc55.33bn308.75m12.85bn334.0040.461.4311.900.232229.4629.465,278.63831.732.2417.684.12165,663,400.001.252.643.286.459.6011.080.5581.281.23--0.002563.099.752.42137.18-12.33-2.4315.81
Japan Medical Dynamic Marketing Inc24.58bn-1.05bn13.11bn538.00--0.519224.270.5331-40.02-40.02933.26953.320.72020.63684.3445,695,190.00-3.134.27-3.804.9459.9365.20-4.355.781.2812.480.180228.508.356.79-136.31---1.378.45
OLBA Healthcare Holdings Inc124.48bn1.43bn13.28bn1.39k8.811.066.350.1066241.07241.0721,003.792,008.322.7716.234.8089,362,800.003.173.439.9111.3911.2611.491.151.220.958266.630.225530.513.492.61-4.6834.3828.7114.87
Daiken Medical Co Ltd10.17bn981.12m15.22bn180.0014.001.7818.221.5034.1534.15353.89267.890.90354.564.9256,482,360.008.727.8611.8311.2538.7941.239.659.511.89183.100.193969.412.073.1511.035.01-0.18892.83
Hoshi Iryo-Sanki Co Ltd15.19bn1.46bn17.07bn500.0010.650.813115.831.12468.70468.704,866.416,137.370.619926.896.0430,379,100.006.006.007.337.6150.3348.989.679.193.22--0.0015.312.196.784.2114.77-18.276.96
Seed Co Ltd33.55bn1.38bn17.95bn985.0013.050.97173.820.53545.4445.441,108.41610.280.64592.487.2834,057,800.002.652.314.163.9444.8442.204.113.300.65357.070.576336.012.580.8892-44.3833.9912.644.56
Medius Holdings Co Ltd291.70bn1.41bn18.41bn2.61k13.070.91774.780.063163.3463.3413,103.95902.232.5418.644.99111,591,700.001.231.654.596.0311.9112.070.48340.64920.912616.510.563828.5711.126.5322.307.6516.287.39
Techno Medica Co Ltd9.89bn985.84m20.90bn244.0016.771.1719.282.11142.26142.261,427.712,040.010.59871.864.3740,546,380.005.976.586.977.7948.5949.669.9612.305.31--0.0040.22-3.680.1936-25.480.0825-40.566.77
Japan Tissue Engineering Co., Ltd.2.26bn-461.45m22.50bn204.00--4.27--9.96-11.36-11.3655.62129.740.36614.015.6311,071,850.00-7.48-4.87-8.33-5.5159.6259.41-20.43-15.896.59--0.00---2.341.23-278.32--0.5717--
Findex Inc5.90bn1.18bn24.56bn311.0019.904.3116.324.1646.3946.39232.45214.020.94678.734.9918,984,330.0019.2116.4821.5419.1963.7758.1820.2916.354.18--0.0034.7312.516.419.7518.41-4.0213.40
Data as of Feb 06 2026. Currency figures normalised to Seed Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.73%Per cent of shares held by top holders
HolderShares% Held
Meiji Yasuda Asset Management Co. Ltd.as of 20 Dec 2024352.30k1.16%
Dimensional Fund Advisors LPas of 08 Jan 202691.20k0.30%
Amova Asset Management Co., Ltd.as of 07 Nov 202447.70k0.16%
Victory Capital Management, Inc. (Investment Management)as of 31 Dec 20256.80k0.02%
American Century Investment Management, Inc.as of 08 Jan 20266.60k0.02%
Goldman Sachs Asset Management LPas of 22 Sep 20256.20k0.02%
Dimensional Fund Advisors Ltd.as of 30 Nov 20255.70k0.02%
DFA Australia Ltd.as of 30 Nov 20254.05k0.01%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20252.50k0.01%
State Street Global Advisors (Japan) Co. Ltd.as of 05 Mar 2024600.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.